Literature DB >> 29661969

Mutations in plasmalemma vesicle-associated protein cause severe syndromic protein-losing enteropathy.

Ilse Julia Broekaert1, Kerstin Becker1,2, Ingo Gottschalk3, Friederike Körber4, Jörg Dötsch1, Holger Thiele5, Janine Altmüller5, Peter Nürnberg5, Christoph Hünseler1, Sebahattin Cirak1,2.   

Abstract

BACKGROUND: Protein-losing enteropathy (PLE) is characterised by gastrointestinal protein leakage due to loss of mucosal integrity or lymphatic abnormalities. PLE can manifest as congenital diarrhoea and should be differentiated from other congenital diarrhoeal disorders. Primary PLEs are genetically heterogeneous and the underlying genetic defects are currently emerging.
OBJECTIVES: We report an infant with fatal PLE for whom we aimed to uncover the underlying pathogenic mutation.
METHODS: We performed whole exome sequencing (WES) for the index patient. Variants were classified based on the American College of Medical Genetics and Genomics guidelines. WES results and our detailed clinical description of the patient were compared with the literature.
RESULTS: We discovered a novel homozygous stop mutation (c.988C>T, p.Q330*) in the Plasmalemma Vesicle-Associated Protein (PLVAP) gene in a newborn with fatal PLE, facial dysmorphism, and renal, ocular and cardiac anomalies. The Q330* mutation is predicted to result in complete loss of PLVAP protein expression leading to deletion of the diaphragms of endothelial fenestrae, resulting in plasma protein extravasation and PLE. Recently, another single homozygous stop mutation in PLVAP causing lethal PLE in an infant was reported.
CONCLUSIONS: Our findings validate PLVAP mutations as a cause of syndromic PLE. Prenatal anomalies, severe PLE and syndromic features may guide the diagnosis of this rare disease. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  congenital diarrhea; plvap; protein-losing enteropathy; syndrome; whole exome sequencing

Mesh:

Substances:

Year:  2018        PMID: 29661969     DOI: 10.1136/jmedgenet-2018-105262

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  6 in total

1.  The fenestrae-associated protein Plvap regulates the rate of blood-borne protein passage into the hypophysis.

Authors:  Ludmila Gordon; Janna Blechman; Eyal Shimoni; Dvir Gur; Bela Anand-Apte; Gil Levkowitz
Journal:  Development       Date:  2019-12-02       Impact factor: 6.868

Review 2.  The role of plasmalemma vesicle-associated protein in pathological breakdown of blood-brain and blood-retinal barriers: potential novel therapeutic target for cerebral edema and diabetic macular edema.

Authors:  Esmeralda K Bosma; Cornelis J F van Noorden; Reinier O Schlingemann; Ingeborg Klaassen
Journal:  Fluids Barriers CNS       Date:  2018-09-20

3.  Clinical outcomes of two patients with a novel pathogenic variant in ASNS: response to asparagine supplementation and review of the literature.

Authors:  Rosanne Sprute; Didem Ardicli; Kader Karli Oguz; Anna Malenica-Mandel; Hülya-Sevcan Daimagüler; Anne Koy; Turgay Coskun; Haicui Wang; Meral Topcu; Sebahattin Cirak
Journal:  Hum Genome Var       Date:  2019-05-22

4.  Phorbol esters induce PLVAP expression via VEGF and additional secreted molecules in MEK1-dependent and p38, JNK and PI3K/Akt-independent manner.

Authors:  B JoNell Hamilton; Dan Tse; Radu V Stan
Journal:  J Cell Mol Med       Date:  2018-11-05       Impact factor: 5.310

5.  Stimulatory G-Protein α Subunit Modulates Endothelial Cell Permeability Through Regulation of Plasmalemma Vesicle-Associated Protein.

Authors:  Lifan He; Hanlin Lu; Xuyang Ji; Jianying Chu; Xiaoteng Qin; Min Chen; Lee S Weinstein; Jiangang Gao; Jianmin Yang; Qunye Zhang; Cheng Zhang; Wencheng Zhang
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

6.  PLVAP is associated with glioma-associated malignant processes and immunosuppressive cell infiltration as a promising marker for prognosis.

Authors:  Kaiming Ma; Xin Chen; Xiaofang Zhao; Suhua Chen; Jun Yang
Journal:  Heliyon       Date:  2022-08-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.